These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

618 related items for PubMed ID: 26290395

  • 1. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study.
    Yin J, Wang J, Pu R, Xin H, Li Z, Han X, Ding Y, Du Y, Liu W, Deng Y, Ji X, Wu M, Yu M, Zhang H, Wang H, Thompson TC, Ni W, Cao G.
    Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395
    [Abstract] [Full Text] [Related]

  • 2. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis.
    Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G.
    J Natl Cancer Inst; 2009 Aug 05; 101(15):1066-82. PubMed ID: 19574418
    [Abstract] [Full Text] [Related]

  • 3. Combinations of eight key mutations in the X/preC region and genomic activity of hepatitis B virus are associated with hepatocellular carcinoma.
    Park YM, Jang JW, Yoo SH, Kim SH, Oh IM, Park SJ, Jang YS, Lee SJ.
    J Viral Hepat; 2014 Mar 05; 21(3):171-7. PubMed ID: 24344773
    [Abstract] [Full Text] [Related]

  • 4. Naturally occurring basal core promoter A1762T/G1764A dual mutations increase the risk of HBV-related hepatocellular carcinoma: a meta-analysis.
    Yang Z, Zhuang L, Lu Y, Xu Q, Tang B, Chen X.
    Oncotarget; 2016 Mar 15; 7(11):12525-36. PubMed ID: 26848866
    [Abstract] [Full Text] [Related]

  • 5. Genomic change in hepatitis B virus associated with development of hepatocellular carcinoma.
    Lee D, Lyu H, Chung YH, Kim JA, Mathews P, Jaffee E, Zheng L, Yu E, Lee YJ, Ryu SH.
    World J Gastroenterol; 2016 Jun 21; 22(23):5393-9. PubMed ID: 27340355
    [Abstract] [Full Text] [Related]

  • 6. A population-based cohort study for the risk factors of HCC among hepatitis B virus mono-infected subjects in Japan.
    Kusakabe A, Tanaka Y, Inoue M, Kurbanov F, Tatematsu K, Nojiri S, Joh T, Tsugane S, Mizokami M.
    J Gastroenterol; 2011 Jan 21; 46(1):117-24. PubMed ID: 20820820
    [Abstract] [Full Text] [Related]

  • 7. Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: a population-based cohort study.
    Wang JP, Kao FY, Wu CY, Hung YP, Chao Y, Chou YJ, Li CP.
    Cancer; 2015 May 01; 121(9):1446-55. PubMed ID: 25537961
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mutational complex genotype of the hepatitis B virus X /precore regions as a novel predictive marker for hepatocellular carcinoma.
    Jang JW, Chun JY, Park YM, Shin SK, Yoo W, Kim SO, Hong SP.
    Cancer Sci; 2012 Feb 01; 103(2):296-304. PubMed ID: 22136288
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma.
    Ji X, Zhang Q, Li B, Du Y, Yin J, Liu W, Zhang H, Cao G.
    Infect Genet Evol; 2014 Dec 01; 28():201-9. PubMed ID: 25281206
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma.
    Honda M, Shirasaki T, Terashima T, Kawaguchi K, Nakamura M, Oishi N, Wang X, Shimakami T, Okada H, Arai K, Yamashita T, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S.
    J Infect Dis; 2016 Apr 01; 213(7):1096-106. PubMed ID: 26621908
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Genetic variability of hepatitis B and C viruses in Brazilian patients with and without hepatocellular carcinoma.
    Araujo OC, Barros JJ, do Ó KM, Nabuco LC, Luz CA, Perez RM, Niel C, Villela-Nogueira CA, Araujo NM.
    J Med Virol; 2014 Feb 01; 86(2):217-23. PubMed ID: 24338810
    [Abstract] [Full Text] [Related]

  • 16. [Analysis of the relationship between hepatitis B virus precore and basal core promoter mutations and acute-on-chronic liver failure].
    Ma XY, Han T, Pei YZ, Zhao ZG, Gao YT, Li Y, Jing L.
    Zhonghua Gan Zang Bing Za Zhi; 2012 Sep 01; 20(9):644-8. PubMed ID: 23207226
    [Abstract] [Full Text] [Related]

  • 17. Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection.
    Hosaka T, Suzuki F, Kobayashi M, Seko Y, Kawamura Y, Sezaki H, Akuta N, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.
    Hepatology; 2013 Jul 01; 58(1):98-107. PubMed ID: 23213040
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A matched case-control study of hepatitis B virus mutations in the preS and core promoter regions associated independently with hepatocellular carcinoma.
    Liu S, Xie J, Yin J, Zhang H, Zhang Q, Pu R, Li C, Ni W, Wang H, Cao G.
    J Med Virol; 2011 Jan 01; 83(1):45-53. PubMed ID: 21108338
    [Abstract] [Full Text] [Related]

  • 20. Combination of preS deletions and A1762T/G1764A mutations in HBV subgenotype C2 increases the risk of developing HCC.
    Lee MH, Kim DY, Kim JK, Chang HY, Kang SH, Ryu HJ, Ju HL, Kim SU, Lee JM, Park JY, Han KH, Chon CY, Ahn SH.
    Intervirology; 2012 Jan 01; 55(4):296-302. PubMed ID: 21865669
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.